Bioblast Pharma

Company Overview

Snapshot

Founded in January 2012, Bioblast Pharma operates with 1–10 employees. The company raised $39.75 million across two funding rounds. In April 2019, Bioblast Pharma delisted from NASDAQ due to a merger, ceasing operations.

Business overview

Bioblast Pharma is a biotechnology company focused on developing therapeutic agents for patients with rare and ultra-rare genetic diseases. The company builds a diverse portfolio of product candidates, including Cabaletta, a mutant protein-stabilizing platform, BBrm, a read-through platform for genetic defects, and mPRT, a mitochondrial protein replacement platform. These technologies aim to treat conditions like OPMD, SBMA, SCA3, and other mitochondrial protein deficiency diseases, operating within the Health Tech & Life Sciences sector.

Strategic signal

In March 2019, Bioblast Pharma merged with Enlivex Therapeutics, which was developing a treatment for graft versus host disease. This strategic move resulted in Bioblast Pharma's delisting from NASDAQ and marked a significant shift in its operational status, signaling a pivot away from its original focus on rare genetic diseases through a corporate integration.

Company Intelligence Q&A

What was a significant corporate event for Bioblast Pharma in 2019?

In April 2019, Bioblast Pharma delisted from NASDAQ due to a merger, which also led to the company ceasing its operations.

When did Bioblast Pharma conduct its Initial Public Offering?

Bioblast Pharma conducted its Initial Public Offering in August 2014 on NASDAQ, raising $35 million in capital.

What was the total capital raised by Bioblast Pharma?

Bioblast Pharma raised a total of $39.75 million across its funding rounds.

What is the primary focus of Bioblast Pharma's therapeutic development?

Bioblast Pharma focuses on developing therapeutic agents for patients with rare and ultra-rare genetic diseases, utilizing platforms like Cabaletta, BBrm, and mPRT.

What was the outcome of the merger involving Bioblast Pharma in March 2019?

In March 2019, Bioblast Pharma completed its merger into Enlivex Therapeutics, a company developing treatments for graft versus host disease.